What is Migraine?
Migraine is a neurovascular disorder characterized by recurrent attacks of moderate–severe head pain (often unilateral, throbbing) with photophobia, phonophobia, nausea/vomiting, and sometimes aura (visual or sensory disturbances). It reflects abnormal excitability in cortico-trigeminovascular pathways, with CGRP release, sterile neuroinflammation, and central sensitization driving pain and hypersensitivity. Care divides into acute (treat the attack: triptans/ditans, gepants, NSAIDs/antiemetics) and preventive therapies (CGRP mAbs/gepants, beta-blockers, topiramate, onabotulinumtoxinA, lifestyle/sleep/behavioral strategies). Against this backdrop, many people ask whether cannabidiol (CBD) can help—either to abort attacks or as prevention.
What the research says: Evidence for CBD & migraine
Meta-analyses & reviews
Systematic and narrative reviews conclude cannabis-based products may help some migraine outcomes, but most human signals involve THC or THC+CBD , not CBD alone; higher-quality RCTs are needed—especially for CBD-only .
A 2025 review of phytocannabinoids and migraine highlights the first RCT of vaporized cannabis for acute attacks and preclinical mechanisms (CGRP, trigeminovascular modulation), while noting CBD-only human data remain sparse .
Clinical / human trials
- Acute treatment—vaporized cannabis (double-blind, placebo-controlled, crossover RCT; N=92; 247 attacks): Four arms per patient (6% THC; 11% CBD; 6% THC + 11% CBD ; placebo). The THC+CBD combo was superior to placebo at 2 h for pain relief, pain freedom, and MBS freedom , with sustained benefits at 24–48 h and no serious AEs . CBD-dominant was not superior to placebo at 2 h (though some 1-h signals appeared), and THC-dominant improved 2-h pain relief only. | Crossover RCT · Vaporized
- Nabilone (THC analogue) reduced headache indices and analgesic intake more than ibuprofen; not CBD but relevant to overuse considerations — medication-overuse headache — nabilone vs ibuprofen. | Crossover RCT
- Reports suggest decreased attack frequency and symptom burden with cannabis use, but designs are uncontrolled and often THC-rich — observational cohorts/surveys. | Survey
Dose-response & dosing
Acute attacks: Evidence of benefit comes from inhaled THC+CBD (6%/11%) in the RCT above; CBD alone did not outperform placebo at 2 h . Optimal ratios, potencies, and puff counts need confirmation.
Prevention: No published CBD-only RCTs for migraine prophylaxis as of 2025. Small uncontrolled series with mixed THC/CBD oils report symptom gains but are hypothesis-generating only.
Proposed mechanisms
How might CBD intersect with migraine biology?
CGRP & trigeminovascular signaling: In nitroglycerin-based rodent models, CBD reduced trigeminal hyperalgesia, CGRP, and IL-6 in brainstem/trigeminal tissues—supporting anti-hyperalgesic, anti-inflammatory actions. BioMed Central
Neuroinflammation/oxidative stress: CBD dampens pro-inflammatory cytokines and may modulate NF-κB/NLRP3 pathways implicated in migraine sensitization (preclinical/immune data). Review context.
Receptor/ion channel targets: CBD engages 5-HT1A and TRP (e.g., TRPV1) channels, plausibly influencing nociception and pre-attack anxiety—mechanistic plausibility without definitive migraine-specific clinical proof.
Safety, tolerability, and side effects
CBD is generally well tolerated ; common effects include somnolence, fatigue, GI upset, dry mouth . High oral doses and certain combinations can raise liver enzymes .
Drug interactions: CBD can inhibit CYP3A4/CYP2C19 , potentially increasing levels of anticoagulants, antiepileptics, and other migraine-adjacent meds; review regimens before regular oral CBD use.
THC-related issues: Where THC is included (as in the effective acute RCT arm), expect euphoria, cognitive effects, and sedation —attenuated when combined with CBD vs THC alone in the RCT. Monitor for overuse and legal/safety considerations.
Limitations & uncertainties
CBD-only gap: No convincing CBD-only human evidence for acute or preventive migraine efficacy yet; the pivotal RCT found no 2-h benefit for CBD-dominant vs placebo.
Heterogeneity & bias: Many positive data come from THC-containing or uncontrolled studies with variable products/routes; placebo effects in pain/headache are substantial.
Overuse risk: Any acute treatment used too frequently can contribute to MOH ; cannabinoids are not exempt—apply standard attack-frequency limits. (Context informed by MOH literature and RCT discussion.) BioMed Central+1
What seems plausible & advisable now
For acute migraine , the best current evidence supports inhaled THC+CBD (6%/11%) , which outperformed placebo and showed sustained benefits. CBD alone did not show robust 2-h efficacy. Consider only as adjunct and within local laws , with attention to psychoactive effects and limits to avoid MOH .
For prevention , no CBD-only RCT evidence exists. Stick with guideline-concordant preventives first; if considering cannabinoids, do so clinician-supervised , with clear goals , trial periods , and monitoring .
Regardless of route, use third-party-tested products , track outcomes (2-h pain relief/freedom, MBS, rescue use, monthly migraine days), and review drug interactions —especially if trying oral CBD regularly.
Bottom line: In 2024’s first rigorous RCT, THC+CBD (inhaled)—but not CBD alone—provided clinically meaningful, sustained acute relief. CBD-only remains unproven for both acute and preventive migraine treatment; larger CBD-focused trials are needed to define who benefits, dose/route, and long-term safety.
